1.................................................................................................................

2
..................................................................................?

4
.................................................

5
.............................................................

6
...................................?

8
............................................................

10
.....................................................(Staging)

12
........................................................................................

15
........................................................................

16
......................

19
..................................................................................................

21
....................................

21
...............................................

24
.........................................................................................



.- ,

,

,
"
.

,"

,

'

.Patient Hand Book - IMF

-
."

-

-
.


,

.

-
.




.


.

,

.


,

(
IMF)


.


.

.

,

.


.

,


,

.


.

.


.


.

,


,


.

.

,

1

?


,

, "
Oma" -

-
Myeloma -

)
.
Myelo -


. ( -
)
(

""

.

()


.

.
-

.


,

,


,

.


.

,

,

.


.(1
)

.
MGUS

.


.
Monoclonal Gammopathy of Undetermined Significance

,

MGUS
-

.

10%-


.

1%

:


,

10-30%


.(
) -
( ,)


.


MGUS

.

,

2


MGUS

:1




.

·
MGUS
MGUS
.

· (

,
)
(Monoclonal Gammopathy of
Undetermined Significance)

·
-

,


MGUS


.

-

,

·



·
.

"
CRAB"
"
CRAB"

*
(
mg/dl 10 <)

()

­
C
.
mg/dl 2 <

(
Renal dysfunction)

­
R
.(
g/dl 10 >
)
­
A
.(
)
­
B
.

CRAB

3


.

,



Orange
)
,

,
HIV

,(
)
,(

,

;

. 8

.

60-

.


.40

5-10%

.
.-

,


5-

.

250-

.10,000-

.

1,000-

,

4



,

,

,


.

-

-


,

.

,


, ,

,

.

,

,


,

.


, .

.

, .


.

,



,

,

.

,

.

.

,


,-

5

?


,

.""

."
" -
(
)

.(2
)

,

,


,

.
-

.

·

,

,

.

.

,

,

.

·
,

.


.

,-
-
/
.

.

.


.

6


:2





.

·

.

·
.



·


.


(
/
)
.

·


(Bence Jones Protein)
.

·

:

.

·
,


·

·

,

(

)
.

,

:



·
.


,



·



·


·

·

·

·






·


7


-

.

-
,

.

()

-
.

:

5

.(1
)

.(
)

(
)

:

.
G,A,D,E,M

("-"
)

, 65%- ,

.


.

(
G
)-
IgG


,(
A
)-
IgA

.

IgD

IgM
, IgE

.(3
)
-
:1



(

)

30%-


10%-

.(

IgG

)


"

.

(

1-2%)

."
Bence Jones

"

"



,

."

"

,"

"

.

(

)
Freelite Test

.

8


:3


**

*

IgG

IgG
(
)

(
G
)-
IgG

G
-

(
L,)

IgA

IgA
(
)

(
A
)-
IgA

A
-
(
L,)


.
IgD- IgM , IgE

*
.

**

IgG
- .

.

IgA

.


IgD


Bence Jones

.

/

.
/
.
9

(
Staging)


.

,


Staging
-

.

(
Stage)


4


.

,
.

Salmon- Durie

Staging-

:4


)
-



*(/
m2
*

600
:

I

10g/dl <

· (
)
mg/dl 10.5>

·

,

·
.

-

(M

)

·
IgG<5g/dl

IgA<3g/dl


·
4g/24h >

*

600-1200
III

I

II

)
(

*
10


-
Salmon- Durie

Staging
-

:4


)
-



*(/
m2

1,200 < *
:

III

8.5g/dl>

· (
)
mg/dl 12 <

·
(scale 3)

·

·
IgG>7g/dl

IgA>5g/dl

12g/24h <

Bence Jones

·

:A·

(mg/dl2 >

)
(
A

B
)

:B·
(mg/dl2
)
:


) IA


) IIIB

,

.(


*
"
,
)
.

("

,

.(5
)
,

11


:5




,

(
S ß2M)

2 microglobulin


,

(
S Alb)


(
CRP) C-reactive protein


(
Lactic Dehydogenase)

LDH

(13
q-) 13



14- 4

FISH


(
Fluorescent In Situ Hybridization)

.(
)
6


:6




,



.


,
-
I

,
)
.

(

,
(
)

/
.FISH

12


-

:6




/

·


·

.1

·

·

.2
LDH-

,(BUN ,

)


.3
.


·

·
.

,

,

(SPEP)

)

·

·

[G, A, D, E]

[()

()

]

SPEP-

·
FREELITE
®

·
.


,

:

.

:

,

(UPEP)

·

·
FREELITE
®

·

,


.
13


-

:6





.

,


,


)
/
,(

.

,

MRI -


/


.

/


.

,

.

/

,

CT scan ­

/

.

.

"
MIBI

-

.


,


PET/FDG


.



,

.




.


,

.

14



(
Staging)

,


.

.

.


:7






-



.





.

.

.(

)






.


.

.

.
/

,


.




.

.

*





,

*
.

15



/
/
:

,

.
?

·

?

·
?
?

?

·
?

·
?

·
.

·
.

·

,

·
.


,

·

.


.

.


,

·
.

16


:8





·
.

·
MP

.

·
(Melphalan / Prednisone)

60%

·

.

.

.

·

·

.


·


/

.


· .

70%

·
VAD

.

· (
Vincristine / Adriamycin

.

.

·
/
Dexamethasone)

.

·

.


Vincristine·
.



Dexamethasone

Dexamethasone
-


.
Dexamethasone

.
VAD
Melphalan
-

,
Melphalan

Dexamethasone
.

.
MP

Melphalan
17


-

:8

)

Dexamethasone

(

. 70%-
Thalidomide

(
DVT)

.

.

,

·

·
VELCADE
®

.

Dexamethasone

,

.

.

·



·

·


.

,


.


·
Cytoxan
®

,


,

·

,

,((
Cyclophosphamide

.

Etoposide
® (VP-

.


.(16

·
:


)
VBMCP·

.(M2

VMCP / VBAP
·
.

.(SWOG

)
UK

)
ABCM·
.(MRC

)
CVAD·
.(


.(
IMF)

, .
18



.

.


:9





,


)

·


,


.


(

.


)

·
(

.


Aredia
®

)

·



2-4

IV
90 mg

,
IV
4 mg

Zomera
® ,


,

.(

15-45


.


·


,
Tylenol®

)
,

,


.

.("
Pain Patch"

Fentanyl
®
.

19


-

:9





.

·
/

,

Neupogen
®·




.
.


·
.(
)
.


·


)

.(

:

,


­

·

,

,

.

.
/

.

­

·

"
"
,

.

.(
)
:

(
"
1000
)
­
C

·
.


­

·

.

.

20


.

­

·

.

.

.

­

·

­

·

.

,

.



.

,

.

(
IMF)

IMF
-

www
.myeloma.org :
.(800) 452-
CURE :


.


.

,


.()

,


.

.

21


,

, .

.

:

.1
?

·
?

·
?

·

?

?

·
)
?


?

,

?( ,

?

?
?

·
?

?

·
?

.2
:


?

?

·
?


?

·
?


?

·
?

)
?

·
.(


,

·

?

, ,
?


,

?

·
?

22


,

.3
/
,

.

,

.

.


?

·

?

?

?
?

?

?


?

·
?


.

.4
:

?

·
?

·
?

·

,


.


,

.

,

,

.

23



()

­

­
Accrual
.

.

­

, ­
Acute
.
cyclophosphamide

melphalan

­
Alkylating Agent
(
) "
Alkylating

.

. ,"
Transplantation"

­
Allogeneic
)
­

­
Amyloidosis
-

.

(` -

,

.
`

,

.


.

,

­
Analgesic
.


,

­

­
Analog
.


,

­

­
Anemia

.

g
/dL 13-14

.
10g/dL

.

,

24


.

­

,

­
Anesthesia
.

.


­

­
Angiogenesis
.

,

­

­
Angiogenesis Inhibitors
.

.

­

­
Antibiotics
(
)
­

­
Antibody

.

, ,

.

.


.

,


.

.

.

­
Antiemetic Drug
.

­
Antifungal Agent

(

,
)
­

­
Antigen
.


,

­
Antineoplastic Agent
.

(
)"
­
Appendicular Skeleton
.

,

,

­
Apoptosis
.

25

.

, .

,

­
Aspiration
indolent
,

.

­
Asymptomatic Myeloma
.

smoldering
.

, ­
Axial Skeleton

,

­
B Cells
.
B

.

.

.

, ­
Basophile
`
-

.

­
Bence Jones

,

.


,

(

0.1
)
.
`
-

.` -

MGUS
.

.

, ­
Benign
.


.

­
Beta 2 Microglobulin (ß2M)

.


10%-

.
/

ß
2M

.
ß2M


ß
2M

.

ß
2M

90%- , .

.

­

­
Biopsy
.

,

­

­
Bisphosphonate
.(
)
(
)
26

,

.

­

­
Blood Cells
.


,

­

­
Blood Count
.


­

­
Bone Marrow
.

,


,

, ­

­
Bone Marrow Aspiration
.


,

, ­

­
Bone Marrow Biopsy

.

.


.

,
.

,)

­
Bone Remodeling

(
)
(

.


­

­
BUN (Blood Urea Nitrogen)

.

BUN
.

.
BUN

,

,


­

, ­
Calcium
.
hydroxyapatite-
.

­

­
Cancer

.

27

.

­

­
Carcinogen

­
CAT (Computerized Axial Tomography) scan

,

CT

.

.(
Computerized Tomography)

­

, ­
Catheter

(
CVC)

.


,

.

.

,
.

­

­
Cell
)
­

-
Cell Differentiation

()

(
.

­

­
Cell Proliferation
.


­

­
Chemotherapy
.

,

­
Combination Chemotherapy ·
.


.
"
­

­
Chromosome
46

,

.

.
.

­

­
Chronic
28

.

­

­
Clinical

.

­
Clinical Trial
.

, ,


­

­
Control Group ·
.


.

;

­
End Point ·
.

,


­

­
Experimental Group ·
.


­
Randomized Clinical Trial ·
.

(
)
MDT
-

­
Phase I Trial ·

.


I

,


.

.

I
;


3-6

(
cohorts)

I

,

.

.



,

,

,

.(
DLT - dose limiting toxicity)

.
II

.


­
II

­
Phase II Trial ·

14-50 ,

.
I

29


.

,

,

.
III

,

II

.

,

.
II

III

,

.
III

­
Phase III Trial ·

.

(
stage)

,

III

.


III

.


III

.

50


III

.

,

II


III

.

.


.

­

­
Creatinine

,

.

.

.

­

­
Cyst

­

­
Cytokine

,
)
.

.

(

­
DEXA (Dual Photon X-ray Absorptionmetry) study
.

.


­

­
Dexamethasone
.
30

.

­

­
Diagnosis

,

­

­
Dialysis
.


­
Disease Free Survival
.

­
DLT (Dose Limiting Toxicity)
.


;

­
DNA
.


.

­
Drug Resistance
.

.

. , ­
Edema

"
efficacy"

,

.

­
Efficacy
.


()

­
Electrophoresis

,

.


(
M
)

.

.
.

­

­
Enzyme

.(
RBC)

,

­

­
Erythrocytes
.

,

31


.

­

-
Erythropoietin
.


.


.

,
.

,


,

,

­
Free Light Chains
.
Freelite test-

,


,

."
"
­

­
Gene

,

.

,

.
.

­

­
Gene Therapy

,


.

,

.

.
"
­

, ­
Genetic

­

­
Graft-versus-host disease (GVHD)
.


, .

­

­
Granulocyte
.


.

­

­
Hematocrit (Hct)
.

.

­

­
Hematologic
.

­

­
Hematologist
32


,

­
Herpes Simplex
."
cold sores"

,

,

­
Herpes Zoster
.

.

­

­
Hormones
.


­
Human leukocyte antigen (HLA) test
.


.

­

­
Hypercalcemia

,

, , , ,

,


.
,

.


,

.


,

.


A
- G .

-
IgG, IgA

,

,

.


, .

,

(
G
)
IgG
-

IgG
)"

.

.(
,

.

.
'
-

,

.

­
IgD, IgE
33


.
Waldenstrom's macroglobulinemia-

­
IgM
.


­

­
Immune System
.

, ,


.

, ­
Immunodeficiency
.

­
Immunofixation
M
(IgG,-

,

.

immunostaining

.(

,
IgA
.(
M
)

,

­

­
Immunoglobulin (Ig)
.

()

.

.
IgA, IgG, IgM, IgD, IgE


­

­
Immunosuppression

,

.


,

.


.

­
Immunotherapy
.

.

­

­
Incidence

­
Induction Therapy
.


.

­
Informed Consent


,

, ,

.

.

,

,
34

.

.

­
Infusion

­
Infusion Pump
.

.

,

.

­
Inhibit
.

.

­
Injection

()

­
Interferon
.



(
)
""

,

.

,


,

­
Interleukin

.(
)
,

(
IL-2) 2

.



(
IL-6) 6

.

.

.

,

­
LDH

()

.

, ­
Lesion
-
Lesion

, .

.


.

.

, ­
Leukocytes
.(
WBC)

.

­
Leukopenia
35

.

­
Lymphocytes

.

­
Lytic Lesions

.

,
.


­
M proteins (M spike)

M spike

.


.
M

.


.

­
Maintenance Therapy
.


.

, ­
Malignant
.

,

­
MDR (Multi Drug Resistance)

.

,
vincristine- adriamycin-


.

p
-glycoprotein

.


.

­ Melanoma
.

,


.

,

­ Metastasize

,


.()

.

,

( ,
)
36


­
MGUS (Monoclonal Gammopathy of Undetermined Significance)
.

M

,

,

­
Molecule
.


.

­
Monoclonal
,

,

.()


.()

.

(
M spike)


.

­
Monoclonal Antibodies

.


,

.

.

, ­
Monocyte

­
MRI (Magnetic Resonance Imaging)

,

,

,

MRI
.
.


­
MTD (Maximum Tolerated Dose)
.


­
Myelodysplastic Syndrome
.

.

.
myelogenous

.

,

­
Myeloid
.

37


,

­
Myelosuppression
.

.

,

,

­
Neoplasia

,

.

­
Neoplasm
.

(
)
.

­
Neutropenia

,

.


.

,
.(®
Neupogen
)
G
-CSF

.

, ­
Neutrophils

,

. ­
Oncogene

(
)

.

,

.


.

, ­
Oncologist
.


, ­
Osteoblast
. ,

,

,

­
Osteoclast

.

,


. (
)
.

.

, ­
Osteoid
38


,

­
Osteonecrosis of the jaws
.

,


,

.

­
Osteoporosis

.
.


.

­
Palliative Treatment

,

.
.

­
Pathological Fracture

,

.


,

­
Pathology
.

.

­
PET (Positron Emission Tomography) scan

PET

.

.


(
)
.

, ­
Placebo
.


,

,

­
Plasma
.


.

.

­
Plasma cells

.


.

.

,


.
M

,
.(

,
)"
39


.
-
­
Plasmacytoma
.

,

-
.

­
Plasmapheresis
.


.

.

­
Platelet

.

.
.

.


­
Port-Implanted

, .

,

.

.


,

.

.

­
Prognosis
.
.

­
Progression Free Survival

,

,

.
.

.

­
Progressive disease

,

­
Protocol
.
,

,

.

­
Precancerous
.


,

­
Radiation Therapy
(
external radiation)

.

.(
implant radiation)

40

.

,

­
Radiologist
.

,

,

.

­
Recurrence
,

,

­
Red Blood Cells (Erythrocytes)

.


.

()


.


.

,

.


,

.
.

­
Refractory
.

­
Regression

­
Relapse
.

­
Remission, Response
.

.
/
M

CR
,

­
Complete Remission (CR) ·
/
;


;

.

CR
.

,

PR
,

­
Partial Remission (PR) ·

.50-75%

PR

,
SWOG

.
CR
.50%

PR
41


­
RNA (ribonucleic acid)

­

RNA
.

RNA
-

R.NA
(deoxy-ribonucleic acid). RNA
.


­
Serum Osteocalcin

.

.
.

.
Herpes Zoster

,

­
Shingles
.

.

­
Side Effects
,

,

,

.


.

­
Skeletal Survey (metastatic survey)
/
, ,

,
.

,

­
Stable Disease

.

50%-


.

(
PR

CR
-
) -
.

,

.

­
Stage
.

­
Staging

.

.

­
Stem Cells
.

,

,

.

42


.

,

­
Steroid
.


,

.

­
Supportive Care
.


­
Systemic Therapy
.

.
Platelets

, ­
Thrombocytes
450,000 - 150,000

.

­
Thrombocytopenia

.

50,000-

.10,000-


,

­
TNF (Tumor Necrosis Factor)
.

.

,

.

­
Toxins
.

­
Transfusion

,

­
Transplantation

.
/
.


.

­
Bone Marrow Transplantation ·

.

.

,

,

­
Peripheral blood stem cell transplantation ·

,

(
)

.

.

43

.()

()

­
Allogeneic ·
.

,


­
Autologous ·
.

,


­
Matched unrelated donor transplants (MUDs) ·

,


,

.

.

.

­
Syngeneic ·

.

.

­
Tumor
.

.


­
Tumor Marker
.

, (
)
.

­
Vaccine

,

.

.

.

, ­
Virus

.

.


­
Waldenstrom's macroglobulinemia
.

.
IgM

.

­
White Blood Cells (WBCs)

.

,


.

.

, ,

.

­
X ray
.

,
44

"
IMF
.... "
.
(IMF)


-
"
56514

, 2020 ..
03-7360085 .
Email
: info@amen.org.il

.

© 2004
International Myeloma Foundation
45